Evolve Private Wealth LLC Has $2.14 Million Stock Position in Abbott Laboratories $ABT

Evolve Private Wealth LLC reduced its holdings in Abbott Laboratories (NYSE:ABT) by 50.8% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 20,807 shares of the healthcare product maker’s stock after selling 21,473 shares during the period. Evolve Private Wealth LLC’s holdings in Abbott Laboratories were worth $2,136,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the business. Baugh & Associates LLC grew its position in Abbott Laboratories by 13.8% during the 1st quarter. Baugh & Associates LLC now owns 58,296 shares of the healthcare product maker’s stock worth $5,985,000 after acquiring an additional 7,073 shares during the last quarter. Forbes J M & Co. LLP raised its position in Abbott Laboratories by 1.2% in the 1st quarter. Forbes J M & Co. LLP now owns 141,209 shares of the healthcare product maker’s stock valued at $14,498,000 after purchasing an additional 1,675 shares during the last quarter. Sky Investment Group LLC boosted its stake in Abbott Laboratories by 0.9% in the first quarter. Sky Investment Group LLC now owns 103,773 shares of the healthcare product maker’s stock worth $10,654,000 after purchasing an additional 892 shares in the last quarter. Triad Wealth Partners LLC boosted its stake in Abbott Laboratories by 4.0% in the first quarter. Triad Wealth Partners LLC now owns 10,738 shares of the healthcare product maker’s stock worth $1,102,000 after purchasing an additional 415 shares in the last quarter. Finally, Kavar Capital Partners Group LLC grew its holdings in shares of Abbott Laboratories by 0.8% during the first quarter. Kavar Capital Partners Group LLC now owns 40,073 shares of the healthcare product maker’s stock worth $4,114,000 after purchasing an additional 328 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $115.00 price target on shares of Abbott Laboratories in a report on Monday. UBS Group decreased their price objective on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Wells Fargo & Company dropped their target price on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Royal Bank Of Canada reduced their target price on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Finally, Mizuho decreased their price target on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.30.

Insider Transactions at Abbott Laboratories

In other news, CFO Philip P. Boudreau purchased 2,200 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

ABT stock opened at $87.78 on Tuesday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The company has a market cap of $152.90 billion, a P/E ratio of 24.59, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. The business’s fifty day moving average is $89.78 and its 200-day moving average is $106.18.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s payout ratio is presently 70.59%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.